Politics / Brazil
Anabolic Steroid Market in Brazil
Doctors continue to sell anabolic implants despite a ban on their aesthetic use, capitalizing on a lucrative market for hormonal treatments. These implants, including testosterone and gestrinona, are marketed for conditions like menopause and anti-aging, despite a lack of safety studies.
Source material: Doctors explore loophole and continue selling anabolic steroids after ban for aesthetic purposes #g1
Summary
Doctors continue to sell anabolic implants despite a ban on their aesthetic use, capitalizing on a lucrative market for hormonal treatments. These implants, including testosterone and gestrinona, are marketed for conditions like menopause and anti-aging, despite a lack of safety studies.
The Brazilian health agency, ANVISA, initially prohibited these implants but reversed the decision under market pressure, allowing their ongoing sale. This reversal raises significant ethical concerns regarding patient safety and the commercialization of healthcare.
Many doctors prescribe these implants without adequate patient evaluation, and some profit from their production through pharmacies. Financial incentives are substantial, with doctors potentially earning up to 20 times the cost of the implants.
Legal actions are being pursued against certain practitioners, yet the market remains strong. Compounding pharmacies generated over 11 billion reais from these products between 2019 and 2023, indicating a thriving underground market.
Perspectives
Proponents of Anabolic Implants
- Claim that hormonal implants are beneficial for conditions like menopause and anti-aging
- Argue that the market for these products is driven by patient demand
Opponents of Anabolic Implants
- Highlight the lack of safety studies and potential health risks associated with these implants
- Criticize the commercialization of healthcare and the ethical implications of profit-driven practices
Neutral / Shared
- Regulatory actions have been taken against certain practitioners in the market
Metrics
revenue
11 billion reais BRL
total revenue generated by compounding pharmacies from hormonal products
This figure highlights the scale of the market and the financial stakes involved in the sale of these implants
the pharmacies of manipulation that are no longer 9,000 units in the country faturized more than 11 billion reais
20 times more times
profit margin for doctors prescribing hormonal implants
Such a high profit margin raises ethical concerns about the motivations behind prescribing these treatments
the doctor reaches 20 times more
Key entities
Key developments
Phase 1
Doctors are continuing to sell anabolic implants despite a ban on their aesthetic use, capitalizing on a lucrative market for hormonal treatments. The Brazilian health agency, ANVISA, initially prohibited these implants but reversed the decision under market pressure, leading to ethical concerns regarding patient safety and healthcare commercialization.
- Doctors are circumventing a ban on aesthetic use by continuing to sell anabolic implants, tapping into a billion-dollar market for hormonal treatments
- Hormonal implants, including testosterone and gestrinona, are marketed for conditions like menopause and anti-aging, despite a lack of safety studies
- The Brazilian health agency, ANVISA, initially banned these implants but reversed the decision due to market pressure, allowing their ongoing sale
- Many doctors prescribe these implants without adequate patient evaluation, and some profit from their production through pharmacies
- Financial incentives are substantial, with doctors potentially earning up to 20 times the cost of the implants, raising ethical concerns about the commercialization of healthcare
- Legal actions are being pursued against certain practitioners, yet the market remains strong, with compounding pharmacies generating over 11 billion reais from these products between 2019 and 2023